TAK
Takeda Pharmaceutical Co Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Takeda Pharmaceutical Co Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No thesis.
Linked news
News
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Capital Research Global InvestorsCapital Research Global Investors | $309.3M | 18.23% | +1.01% | |
| 2 | FMRFMR | $153.9M | 9.07% | +34.87% | |
| 3 | Morgan StanleyMorgan Stanley | $112.1M | 6.61% | +8.12% | |
| 4 | Adage Capital Partners GPAdage Capital Partners GP | $97.0M | 5.72% | −5.82% | |
| 5 | Goldman Sachs GroupGoldman Sachs | $82.2M | 4.84% | −8.79% | |
| 6 | Brandes Investment PartnersBrandes Investment Partners | $72.8M | 4.29% | +2.45% | |
| 7 | Arrowstreet Capital, Limited PartnershipArrowstreet Capital, Limited Partnership | $59.8M | 3.53% | +19.79% | |
| 8 | BlackRockBlackRockindex-like | $59.1M | 3.49% | +16.11% | |
| 9 | Renaissance TechnologiesRenaissance Technologies | $41.2M | 2.43% | −14.09% | |
| 10 | Qube Research & TechnologiesQube Research & Technologies | $35.4M | 2.09% | new | |
| 11 | First Trust AdvisorsFirst Trust | $33.9M | 2.00% | +7.30% | |
| 12 | D. E. ShawD. E. Shaw | $32.9M | 1.94% | −21.25% | |
| 13 | Managed Asset PortfoliosManaged Asset Portfolios | $29.2M | 1.72% | +1.42% | |
| 14 | Northern TrustNorthern Trustindex-like | $27.9M | 1.64% | −11.26% | |
| 15 | VAN ECK AssociatesVAN ECK | $26.8M | 1.58% | −25.93% | |
| 16 | Envestnet Asset ManagementEnvestnet | $25.6M | 1.51% | +13.19% | |
| 17 | AQR Capital ManagementAQR | $24.5M | 1.44% | +70.58% | |
| 18 | Quantinno Capital ManagementQuantinno | $22.5M | 1.33% | +8.79% | |
| 19 | Wells FargoWells Fargo | $18.4M | 1.09% | +1.30% | |
| 20 | Millennium ManagementMillennium | $16.8M | 0.99% | new | |
| 21 | Citadel AdvisorsCitadel | $14.9M | 0.88% | −57.21% | |
| 22 | UBS GroupUBS | $14.6M | 0.86% | −66.74% | |
| 23 | Crossmark Global HoldingsCrossmark Global | $12.6M | 0.74% | +0.86% | |
| 24 | Jane Street GroupJane Street | $12.3M | 0.73% | new | |
| 25 | JPMorgan ChaseJPMorgan Chase | $11.9M | 0.70% | new |
378 managers report $1.7B of Takeda Pharmaceutical on form 13F for the quarter ended Jun 30 '26. 26 of them hold 80% of it; Capital Research Global Investors is largest at 18.23%.
Expected move
No implied move.
No implied move.
No implied move.
Takeda Pharmaceutical Co Ltd
20.81
−0.06 · −0.29%